DIVIDEND ANNOUNCEMENT: Ord Cl A/Royalty Pharma plc (NASDAQ:RPRX) on 10/16/2023 declared a dividend of $0.2000 per share

Ord Cl A/Royalty Pharma plc (NASDAQ:RPRX) on 10/16/2023 declared a dividend of $ 0.2000 per share payable on December 15, 2023 to shareholders of record as of November 17, 2023.

Ord Cl A/Royalty Pharma plc (NASDAQ:RPRX) has paid dividends since 1970, has a current dividend yield of 2.8376436234% and has increased its dividends for 2 successive years.

Ord Cl A/Royalty Pharma plc's market cap is $ 12,498,127,680 and has a PE ratio of 37.62. The stock price closed yesterday at $ 27.84 and has a 52 week low/high of $ 25.92 and $ 44.47.

Royalty Pharma is a buyer of biopharmaceutical royalties. The royalties in Co.'s marketed portfolio related to approved products include: cystic fibrosis franchise, which consists of Co.'s right to receive royalty payments on the sale of various products for use in the treatment of cystic fibrosis, including Kalydeco (ivacaftor), Orkambi (lumacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor and ivacaftor) and Trikafta/Kaftrio (elexacaftor, tezacaftor and ivacaftor); and Tysabri, which is a monoclonal antibody for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

For more information on Ord Cl A/Royalty Pharma plc click here.